Neoadjuvant versus adjuvant radiotherapy for centrally located hepatocellular carcinoma: a propensity score matching study based on two prospective phase II trials.

Therefore, the wider margins achieved in the Neo-IMRT group may have contributed to the numerical trend toward higher survival rates, although this did not reach statistical significance. 22 – 24 Recently, D’Alessio et al. 25 reported that pathological response following neoadjuvant immune therapy was significantly associated with recurrence-free survival (RFS) in patients with HCC.

also in 111,027 other papers